Skip to main content
Premium Trial:

Request an Annual Quote

Maxygen Raises $110 M In Initial Public Offering

Premium

R

EDWOOD CITY, Calif.--Maxygen late last month announced its initial public offering of 6.9 million shares of common stock at $16 per share. Shares opened at $36 and climbed on volume of 7.7 million to close at $42. Net proceeds to Maxygen totaled $102 million. The company said its proprietary MolecularBreeding directed molecular evolution technologies bring together advances in molecular biology and classical breeding while capitalizing on information generated by genomics research. One week after its IPO, Maxygen shares were being traded at over $68.

Filed under

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.